The ACROSSS study asks two linked clinical questions. First, investigators reported they will examine whether taking a nap shortly before an acute cerebrovascular or coronary event is associated with the event's onset using a case-crossover design. Second, the team will assess the incidence and course of sleep disturbances at three and twelve months after an index myocardial infarction or stroke. The protocol specifies sample-size targets for both components — 656 patients for the acute-trigger (case-crossover) arm and 400 patients for the longitudinal follow-up arm — and frames these as the primary operational thresholds for recruitment and analysis.
The study team described a case-crossover approach to evaluate short-term triggers that immediately precede the acute event. In this design, each patient serves as their own control, allowing within-person comparison of exposure during a hazard period immediately before the event versus control periods. The source indicates the exposure of interest is napping shortly before event onset; the precise hazard- and control-period definitions are not reported in the source text. The authors noted that prior literature documents diurnal peaks in myocardial infarction and stroke incidence, with morning and afternoon peaks, but the role of night sleep or napping as proximate triggers has not been previously investigated in this study design.
Investigators plan to measure sleep-related outcomes longitudinally after the index event. The study will estimate the incidence of new or persistent sleep disturbances at three months and again at twelve months. The protocol sets a target of 400 patients for this follow-up evaluation. The source lists follow-up as a descriptive and prospective assessment intended to capture recovery or persistent sleep problems after a cardiovascular event; it does not, however, report specific analytic endpoints or predefined criteria for how sleep disturbance will be categorized for analysis.
Baseline and follow-up data collection combine self-report instruments, structured questionnaires on acute triggers, and objective sleep monitoring. The investigators will use validated questionnaires such as the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale, alongside a case-crossover questionnaire on potential acute triggers and a health and lifestyle questionnaire. Eligible patients will be screened for sleep apnea; the source confirms screening will occur but does not detail the screening modality or diagnostic thresholds. For longitudinal measurement, the study will use actigraphy to record sleep during follow-up; actigraphy is presented as the objective complement to questionnaire data. The protocol text does not provide actigraphy wear schedules, scoring algorithms, or device models in the publicly available abstract.
Recruitment is described as taking place in four German hospitals in Essen and Bottrop, North Rhine-Westphalia. The study authors listed the required sample sizes cited above: 656 for the case-crossover analysis and 400 for the follow-up cohort. The source does not provide a full eligibility criteria table in the abstract; it confirms that patients with an index diagnosis of myocardial infarction, stroke, or transient ischemic attack will be enrolled, but precise inclusion and exclusion criteria, timing of enrollment relative to symptom onset, and procedures for consecutive or convenience sampling are not reported in the excerpt.
The central ethics committee of the University of Duisburg-Essen granted ethical approval for the protocol, and the authors stated that all required patient consent procedures and reporting guidelines were followed. The study team reported that prospective interventional studies were registered and that a trial registration identifier was provided; the source text does not include that registration ID in the abstract. Data produced by the study are available upon reasonable request from the Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, with access contingent on a contractual agreement. Funding sources declared include the German Ministry of Education and Science (BMBF) and the German Heart Research Foundation.
The preprint abstract outlines aims, instruments and recruitment goals but leaves several operational details unspecified in the source text. The hazard- and control-period definitions for the case-crossover exposure window are not reported. Detailed eligibility criteria and enrollment timing relative to event onset are absent from the abstract. The screening method and diagnostic criteria for sleep apnea are not described, nor are actigraphy device specifics or analysis plans provided. Investigators reported no competing interests. Interested clinicians and researchers should consult the full protocol or contact the study group for the trial registration identifier and for access to the complete methods and data-sharing arrangements.